Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2022 16:18 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
April 18, 2022 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
April 12, 2022 23:50 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2022 17:15 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
March 30, 2022 16:02 ET
|
Crinetics Pharmaceuticals, Inc.
– Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021 – – Advancing Phase 3 PATHFNDR Program Evaluating...
Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
March 30, 2022 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...
Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer
March 21, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
March 14, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2022 17:20 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
March 01, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...